![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Australia Approves Smartphone Diagnostic for Acute Pediatric Respiratory Disease
Australia Approves Smartphone Diagnostic for Acute Pediatric Respiratory Disease
![Grey Approved Stamp](https://www.fdanews.com/ext/resources/test/Drug-Images4/Grey_Approved_Stamp.gif?t=1576541258&width=430)
Australia’s Therapeutic Goods Administration (TGA) has approved ResApp’s ResAppDx-EU, a smartphone-based app for diagnosing and managing respiratory disease in pediatric patients.
The app previously received the CE Mark, which was supported by data from a pediatric clinical study showing that the app’s cough-based diagnosis algorithms had “excellent agreement with a clinical diagnosis,” the company said.
The mobile software app is intended for use by clinicians to diagnose lower respiratory tract disease, croup, pneumonia, asthma/reactive airway disease and bronchiolitis in infants and children.
Upcoming Events
-
21Oct